177 related articles for article (PubMed ID: 33743617)
1. Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients.
Law JP; Borrows R; McNulty D; Sharif A; Ferro CJ
BMC Nephrol; 2021 Mar; 22(1):102. PubMed ID: 33743617
[TBL] [Abstract][Full Text] [Related]
2. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
[TBL] [Abstract][Full Text] [Related]
5. Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients.
Vutien P; Perkins J; Biggins SW; Reyes J; Imlay H; Limaye AP
Liver Transpl; 2021 Sep; 27(9):1302-1311. PubMed ID: 33687777
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation.
Le Page AK; Mackie FE; McTaggart SJ; Kennedy SE
Nephrology (Carlton); 2013 Dec; 18(12):813-9. PubMed ID: 23927085
[TBL] [Abstract][Full Text] [Related]
8. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.
Hussain T; Burch M; Fenton MJ; Whitmore PM; Rees P; Elliott M; Aurora P
Circulation; 2007 Apr; 115(13):1798-805. PubMed ID: 17353448
[TBL] [Abstract][Full Text] [Related]
9. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
Santos AH; Casey MJ; Xuerong W; Womer KL
Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
[TBL] [Abstract][Full Text] [Related]
11. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival.
Smedbråten YV; Sagedal S; Leivestad T; Mjøen G; Osnes K; Rollag H; Reisaeter AV; Foss A; Os I; Hartmann A
Clin Transplant; 2014 Jan; 28(1):120-6. PubMed ID: 24351078
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
Opelz G; Daniel V; Naujokat C; Döhler B
Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Disease, Short-Term Cardiovascular Events and Graft Survival in a Cohort of Kidney Transplant Recipients With High CMV IgG Seroprevalence.
Díaz JS; Jaimes FA
Prog Transplant; 2021 Jun; 31(2):126-132. PubMed ID: 33739179
[TBL] [Abstract][Full Text] [Related]
14. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
15. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
16. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
17. Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort.
Pullerits K; Garland S; Rengarajan S; Guiver M; Chinnadurai R; Middleton RJ; Chukwu CA; Kalra PA
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366504
[TBL] [Abstract][Full Text] [Related]
18. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
20. Patient years lost due to cytomegalovirus serostatus mismatching in the scientific registry of transplant recipients.
Abidi MZ; Schold JD; Kaplan B; Weinberg A; Erlandson KM; Malamon JS
Front Immunol; 2023; 14():1292648. PubMed ID: 38264645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
